35 documents

Read All
08:00 , Jan 9, 2012 |  BioCentury  |  Finance

A Remembrance: An authentic giant

A Remembrance: An authentic giant It's been a tough 13 months. Three of the larger-than-life figures in biotech are gone - Frank Baldino of Cephalon Inc. , Jean Deleage of Alta Partners, and now Alex...
Read More
01:24 , Nov 23, 2011 |  BC Extra  |  Top Story

Prospect Venture's Barkas passes away

Prospect Venture Partners said Managing Director Alex Barkas died unexpectedly on Monday. Barkas, 64, joined Prospect in 1997 from Kleiner Perkins Caufield & Byers, where he was a partner from 1991-97. He was the founding...
Read More
08:00 , Oct 30, 2006 |  BioCentury  |  Finance

Connetics chronicles

Connetics chronicles Connetics (CNCT), which last week agreed to be acquired by Stiefel for about $640 million in cash, has seen two big stock runs abruptly cut short when setbacks prompted investors to bail out...
Read More
08:00 , Mar 31, 1997 |  BC Week In Review  |  Clinical News

Connetics regulatory update

CNCT received U.S. Patent No. 5,614,192 covering its T cell receptor (TCR) vaccine technology. The patent claims TCR peptides and functional derivatives encompassing the TCR second complementarity determining region (CDR2) as compositions of matter, formulations...
Read More
08:00 , Mar 31, 1997 |  BC Week In Review  |  Clinical News

Interferon gamma-1b: CNCT completed enrollment in its Phase III trial

Connetics Corp. (formerly Connective Therapeutics Inc. , CNCT), Palo Alto, Calif.   Product: Interferon gamma-1b   Indication: Atopic dermatitis   Status: CNCT completed enrollment in its Phase III double-blind, placebo-controlled trial in severe atopic dermatitis....
Read More
08:00 , Mar 31, 1997 |  BC Week In Review  |  Company News

Connective Therapeutics autoimmune/inflammation, dermatology news

The company changed its name to Connetics Corp. It will continue to trade on NASDAQ under the symbol CNCT. The company develops products for rheumatology and dermatology. Connective Therapeutics Inc. (CNCT), Palo Alto, Calif.  ...
Read More
08:00 , Mar 3, 1997 |  BC Week In Review  |  Clinical News

Gamma interferon data

Positive Phase II results in severe atopic dermatitis were presented at the meeting of the American Academy of Allergy, Asthma and Immunology in San Francisco. The data from the open-label trial in adults and children...
Read More
08:00 , Jan 27, 1997 |  BC Week In Review  |  Clinical News

Gamma interferon: CNCT began Phase II trials

Connective Therapeutics Inc. (CNCT), Palo Alto, Calif.   Product: Gamma interferon   Indication: Keloids   Status: CNCT began Phase II trials in keloids, fibrotic growths that result from excessive collagen formation in the skin during...
Read More
08:00 , Jan 13, 1997 |  BC Week In Review  |  Clinical News

ConXn recombinant relaxin data

CNCT announced that Phase I results show good toleration with no serious adverse events. Improved skin scores also were achieved. The product is in Phase II testing in this indication. The skin scores, a measure...
Read More
08:00 , Jan 13, 1997 |  BC Week In Review  |  Clinical News

Therapeutic vaccine targeted to T cell receptors: Phase I and II Update

Connective Therapeutics Inc. (CNCT), Palo Alto, Calif.   Product: Therapeutic vaccine targeted to T cell receptors   Indication: Multiple sclerosis   Status: CNCT began Phase I/II testing of a T cell receptor vaccine designed to...
Read More